65.33 USD
↗ 4.04 (6.59%)AT CLOSE (11:59 AM EDT)
Tarsus Pharmaceuticals, Inc. Common Stock
TARSNASDAQ • USD
65.24
↘ 0.09 (0.14%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
65.24
↘ 0.09 (0.14%)
Market: CLOSED
Tarsus Pharmaceuticals, Inc. Common Stock (TARS) trades at $65.35 per share. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place TARS at a fair price relative to peers.
Technical & fundamental data as of Aug 6, 2026.
Open?$57.63
High?$66.24
Low?$57.63
Prev. Close?$61.29
Volume?1.6M
Avg. Volume?1.2M
VWAP?$64.05
Rel. Volume?1.33x
Bid / Ask
Bid?$57.11 × 700
Ask?$68.00 × 4.0K
Spread?$10.89
Midpoint?$62.56
Valuation & Ratios
Market Cap?2.7B
Shares Out?43.0M
Float?37.2M
Float %?86.4%
P/E Ratio?N/A
P/B Ratio?7.66
EPS?-$1.12
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Employees
370
Market Cap
2.7B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2020-10-16
Address
15440 LAGUNA CANYON ROAD
IRVINE, CA 92618
Phone: (949) 409-9820
IRVINE, CA 92618
Phone: (949) 409-9820
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?100
Momentum?97
Short Sent.?31
Piotroski F-Score?4/9Mixed
Altman Z-Score?7.31Safe
Confidence?60%Moderate
Short InterestHigh
Short % of Float?15.56%High
Short Interest?5.8M
Days to Cover?3.2
Free Float37.2M
Avg Daily Volume1.8M
Settlement Date2026-07-15
Financial Health
Current Ratio?3.74Strong
Quick Ratio?3.71Strong
Cash Ratio?0.71Adequate
Debt/Equity?0.21Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score75/100
P/E?N/A▾
P/B?7.66FAIR▾
Peers100
S&P24
P/S?5.00FAIR▾
Peers100
S&P29
P/FCF?N/A▾
EV/EBITDA?-47.8CHEAP▾
S&P97
EV/Sales?4.94FAIR▾
Peers100
S&P36
Returns & Efficiency
ROE?-14.0%WEAK▾
S&P9
ROA?-8.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-31539000
Enterprise Value?$2.6B
Fundamentals ratios updated end of day